Ideaya Biosciences, INC 8-K filings

IDEAYA Biosciences successfully closed a public offering of common stock and pre-funded warrants, raising approximately $283.8 million in net proceeds.

IDEAYA Biosciences announced a preliminary cash balance of approximately $952.7 million as of June 30, 2024, and provided an update on its at-the-market offering.

IDEAYA Biosciences reports encouraging interim Phase 2 data for its drug IDE397, showing clinical efficacy and a favorable safety profile in patients with MTAP-deletion urothelial and non-small cell lung cancers.

IDEAYA Biosciences' Chief Legal Officer, Jason Throne, has voluntarily resigned, effective July 11, 2024, due to personal reasons.

IDEAYA Biosciences reported encouraging clinical data from two Phase 2 trials of darovasertib, showing significant tumor shrinkage and eye-saving potential in patients with uveal melanoma.

IDEAYA Biosciences held its 2024 Annual Meeting of Stockholders, where shareholders voted on key proposals including the election of directors and ratification of the company's auditor.

IDEAYA Biosciences announced its first quarter 2024 financial results and provided a business update, highlighting progress across its clinical programs and a strong cash position.

IDEAYA Biosciences and Merck have entered into a clinical trial collaboration to evaluate IDEAYA's IDE161 in combination with Merck's KEYTRUDA for endometrial cancer treatment.

IDEAYA Biosciences announced its fourth quarter and full-year 2023 financial results and provided a business update, highlighting progress across its clinical programs and a strong cash position.

IDEAYA Biosciences has successfully raised $126.9 million through the sale of common stock under its at-the-market offering program.

IDEAYA Biosciences has entered into an agreement with Jefferies LLC for an at-the-market offering of up to $350 million in common stock.

IDEAYA Biosciences has successfully sold 1,561,735 shares for net proceeds of $57 million through its at-the-market offering program.

IDEAYA Biosciences successfully raised $158.9 million through an at-the-market offering of common stock between January 4 and January 11, 2024.